Stem Cells and Exosomes for Longevity and Joints: What the Evidence Shows | Philadelphia

TL;DR30-second take

Stem-cell and exosome treatments are marketed for joint pain, anti-aging, and IV longevity, often for five figures. The underlying biology is promising and legitimate research is ongoing, but the products sold commercially are a different matter: most are not FDA-approved, their benefits are largely unproven, and some have caused serious harm. The old idea that injected stem cells rebuild cartilage or organs is mostly wrong; the cells die within days and any effect comes from short-lived signaling. There are zero FDA-approved exosome products, and the FDA has warned about infections from them. For knee arthritis, the evidence shows at best a small, short-term, largely placebo-driven benefit and no proven cartilage regrowth. For IV longevity there is no human evidence at all. Approved stem-cell medicine does exist, such as bone-marrow transplant for blood cancers, but it is not what a wellness clinic is selling.

TL;DR: Stem-cell and exosome treatments are among the most heavily marketed offerings in the longevity and wellness world, sold for joint pain, anti-aging, and intravenous "longevity" infusions, often at five-figure prices. The honest picture has two halves. The underlying biology is promising, and legitimate research and clinical trials are ongoing. But the products sold commercially are mostly not FDA-approved, their benefits are largely unproven, and some have caused serious harm. The common mental image, that injected stem cells rebuild cartilage or rejuvenate organs, is mostly wrong: the cells die within days and any benefit comes from brief chemical signaling rather than from becoming new tissue. There are no FDA-approved exosome products, and the FDA has warned about infections tied to them. For knee arthritis, the best evidence shows a small, short-term, largely placebo-driven improvement and no proven cartilage regrowth. For IV longevity infusions there is no human evidence at all. Approved stem-cell medicine exists, such as bone-marrow transplant for blood cancers, but it is a world apart from what a wellness clinic injects into a knee.

What are these treatments, and what do they do?

The word "stem cells" is used loosely in this market, and the looseness matters. What clinics inject is usually one of a few things: mesenchymal cells taken from bone marrow, fat, or birth tissue like umbilical cord; or minimally processed preparations such as bone marrow aspirate concentrate or the stromal vascular fraction from fat. Several of these are not purified stem cells at all but mixtures of many cell types. The very term is contested enough that the scientist who coined "mesenchymal stem cell" later argued it should be renamed "medicinal signaling cell," because these cells do not behave like the tissue-rebuilding stem cells people imagine.

That points to the central misunderstanding. The intuitive story is that you inject stem cells, they take up residence, and they grow into new cartilage or fresh young tissue. That is mostly not what happens. Injected cells are short-lived: the large majority die within a few days, and cells given by IV lodge in the lungs and are cleared rather than traveling to repair distant organs.¹ Whatever benefit these treatments produce, and there may be some, comes not from the cells becoming new tissue but from the chemical signals they release while they are briefly alive, a transient anti-inflammatory effect. Understanding that reframes the whole field: these are, at best, short-acting signaling treatments rather than the tissue-regrowth that the marketing implies.

Are they FDA-approved?

For the longevity and joint uses being marketed, mostly no, and this is the heart of the matter. The FDA regulates cell and tissue products, and a narrow category that is only minimally processed and used for the same basic function it had in the body can follow a lighter path. Most of what these clinics sell, including culture-grown cells, fat-derived preparations, umbilical products injected into joints or given by IV, and exosomes, falls outside that narrow category, which makes them unapproved drugs that would legally require FDA approval they do not have.

The regulatory picture has hardened, not softened. The FDA set out its framework in 2017 and allowed a grace period for the industry to comply, which ended in 2021. Since then it has issued over 350 warning and notification letters, and the courts have repeatedly backed its position, up to the Supreme Court declining in 2025 to disturb a ruling that even a person's own fat-derived cell preparation counts as a drug requiring approval.² So the accurate statement is that these products are largely sold outside the approval system, and the legal weight is on the side of the regulators who call them unapproved.

It is worth being clear about what this does not mean, because the opposite error is just as common. Approved stem-cell medicine exists. Bone-marrow and cord-blood transplantation, which restores the blood and immune system, is decades-old, standard, life-saving care for leukemias and other blood disorders, and there are FDA-licensed cord-blood products for it. The point is not that stem cells are fake. It is that the proven, approved uses are specific and narrow, and they are not the knee injection or the longevity drip.

The exosome problem

Exosomes deserve their own note, because they are the newest wave and carry a specific warning. They are tiny packets that cells release to carry signals to other cells, and they are now marketed for skin, hair, joints, and IV longevity. Two facts should anchor any decision about them.

First, there are no FDA-approved exosome products for these uses, none, so anything sold is by definition unapproved. Second, the FDA issued a public safety notification about them in December 2019 after a cluster of patients in Nebraska, fewer than five according to state officials, were hospitalized with serious bacterial infections following treatment with unapproved products marketed as containing exosomes.³ That is the risk in concentrated form: an unapproved biological product, made and handled outside the safety controls of the approval system, can be contaminated, and injecting it can cause a dangerous infection. Promising science does not make a particular vial in a particular clinic safe.

Do they work for knees and joints?

This is the use with the most research, so it is the fairest test, and the answer is a heavily qualified maybe. Some randomized trials of stem-cell injections for knee osteoarthritis have shown improvements in pain and function compared with placebo. But when the trials are pooled and judged carefully, the picture weakens: a major evidence review concluded the injections may slightly improve pain and function, on low-certainty evidence.⁴ The trials tend to be small, differ widely in what they inject, and carry a high risk of bias, and a large share of the apparent benefit appears to be a placebo effect, which is powerful for a painful joint being injected with anything.

Two things are missing that would make the case compelling. There is no convincing evidence that these injections regrow cartilage or change the course of the arthritis, despite that being the central promise. And the major orthopedic guidelines do not endorse them. So the honest read is that a stem-cell or related injection might give some people short-term relief, partly through a placebo response, but it has not been shown to repair the joint or to outperform cheaper, proven options, and it costs a great deal more.

What about IV stem cells for longevity?

Here the evidence thins out to nothing. The idea of an intravenous infusion of stem cells or exosomes that slows aging or extends healthspan is appealing, and there are intriguing signals in aged mice. But there is no rigorous human evidence that any such infusion slows aging or extends healthspan or lifespan in people. The studies that exist are small, short, and not designed to answer that question.

This is why these infusions are so often sold from clinics in places outside FDA jurisdiction, in the Caribbean, Central America, and Mexico, where an unapproved product can be marketed directly to medical tourists. The price tags are large and the oversight is minimal. For a healthy person seeking longevity, an IV stem-cell drip is, on the current evidence, an expensive intervention with no demonstrated benefit and non-trivial risk, which is close to the opposite of what the longevity project should be about.

Are they safe?

Longevity Medicine

A personalized longevity strategy starts with knowing your real baselines.

Start Your Longevity Assessment

Mostly the honest answer is that safety is not established, and some harms are well documented. It is worth separating the two.

The documented harms are concrete. The Nebraska infections tied to exosome products are one example. A starker one: three women with macular degeneration were left blind, some with no light perception at all, after a Florida clinic injected fat-derived "stem cells" into their eyes, a case published in a major medical journal.⁵ These are not hypothetical; they happened to people who paid for treatment. Beyond infection and that kind of direct injury, there are rarer, mostly case-report concerns, including abnormal tissue growths after unproven treatments and, for IV infusions, the risk of cells lodging dangerously in the lungs. The theme is that a product made and given outside the safety system carries risks that a regulated therapy is designed to prevent.

None of this means every clinic is dangerous or every patient is harmed; most are not. But the risk is not zero, the oversight that would catch problems is often absent, and the potential upside, on current evidence, is small. That is an unfavorable trade for most people.

The bottom line: promising biology, unproven products

The fair way to hold this whole field is to keep two truths at once. The biology is truly exciting, and serious researchers are running legitimate clinical trials that may, in time, produce proven regenerative treatments. And the products being sold commercially today, for joints and above all for longevity, are largely unapproved, largely unproven, expensive, and sometimes unsafe.

The distinction that matters most, if you are drawn to this, is between an enrolled clinical trial and a clinic selling a treatment. A legitimate trial has oversight, reports its harms, follows a protocol, and usually costs little or nothing, because you are helping to answer the question. A clinic charging five figures for an unapproved infusion is selling you the hope that the question already has a favorable answer, which it does not yet. If regenerative medicine delivers on its promise, it will do so through that first path, and you will not have to leave the country or empty your savings to benefit.

Guidance from the Clinic

"Patients ask me about this constantly, usually after a slick consultation somewhere, and I try to give them the same balanced answer every time. I am not a cynic about the science; the biology of these cells and the signals they release is one of the more exciting areas in medicine, and I hope the trials pan out. But I separate the science from the sales. What is being sold right now for knees and for longevity is mostly not approved, mostly not proven, and occasionally harmful, and the prices are enormous. The stories that stay with me are the ones where it went wrong, the infections, the people blinded after eye injections. So when a patient is tempted, my advice is simple: if you want in on this, do it through a proper clinical trial with oversight rather than a cash-only clinic. And in the meantime, the things that truly build healthspan, strength, sleep, metabolic health, are not glamorous, but they work and they are safe."

Key Takeaways

Most stem-cell and exosome treatments sold for joints and longevity are not FDA-approved; the FDA's enforcement has tightened, and courts have backed its position that even your own fat-derived cells count as an unapproved drug.
The mechanism is misunderstood: injected cells mostly die within days and do not become new cartilage or tissue; any benefit comes from brief signaling, not regrowth.
There are no FDA-approved exosome products for these uses, and the FDA warned in 2019 about serious infections from unapproved exosome products.
For knee arthritis, the evidence shows at most a small, short-term, largely placebo-driven benefit and no proven cartilage repair; for IV longevity infusions there is no human evidence at all.
Approved stem-cell medicine exists, such as bone-marrow transplant, but it is not the clinic injection or drip; if you are drawn to this, choose a regulated clinical trial over a five-figure cash treatment.

Peptide Therapy in Philadelphia - another emerging therapy, held to the same evidence standard
Rapamycin and Longevity - a longevity intervention with a legitimate research base, soberly assessed
NAD and NMN for Longevity - separating the hype from the evidence on another popular protocol
Healthy Skin Aging - where exosome facials and stem-cell serums fit, on the cosmetic side
Longevity Medicine in Philadelphia - the evidence-based approach to healthspan

Scientific References

Eggenhofer E, Benseler V, Kroemer A, et al. "Mesenchymal Stem Cells Are Short-Lived and Do Not Migrate Beyond the Lungs After Intravenous Infusion." Frontiers in Immunology. 2012;3:297.
US Food and Drug Administration. "Regulatory Framework for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)." 2017; enforcement discretion ended 2021. (See also US v. US Stem Cell, 11th Cir. 2021; US v. California Stem Cell Treatment Center, 9th Cir. 2024, cert. denied 2025.)
US Food and Drug Administration. "Public Safety Notification on Exosome Products." December 6, 2019.
Whittle SL, Johnston RV, Buchbinder R, et al. "Stem Cell Injections for Knee Osteoarthritis." Cochrane Database of Systematic Reviews. 2025;4:CD013342.
Kuriyan AE, Albini TA, Townsend JH, et al. "Vision Loss After Intravitreal Injection of Autologous 'Stem Cells' for AMD." New England Journal of Medicine. 2017;376(11):1047-1053.

Fishtown Medicine | Longevity

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

For joint pain and longevity, mostly no. Bone-marrow and cord-blood transplantation for blood cancers is an approved, established use of stem cells, but the injections and IV infusions sold at wellness and longevity clinics are largely not FDA-approved. Most fall outside the narrow category the FDA allows for minimally processed tissue, which makes them unapproved drugs. The FDA has sent over 350 warning and notification letters, and courts have backed its position that even a person's own fat-derived cell preparation is a drug requiring approval.

There is no convincing evidence that they do, despite that being the main selling point. Injected cells mostly die within days and do not become new cartilage; any benefit comes from short-lived signaling rather than tissue regrowth. For knee arthritis, careful reviews find at most a small, short-term improvement in pain and function on low-certainty evidence, with much of it likely a placebo effect, and no proof that the joint is repaired or the disease slowed.

They are not FDA-approved for these uses, and the FDA has specifically warned about them. In 2019 the agency issued a public safety notification after a cluster of patients in Nebraska were hospitalized with serious bacterial infections from unapproved products marketed as containing exosomes. Because these products are made and handled outside the approval system's safety controls, contamination and infection are documented risks. There are no FDA-approved exosome products for skin, joint, or longevity use.

There is no human evidence that they can. The idea is appealing and there are hints in animal studies, but no rigorous trial has shown that an IV infusion of stem cells or exosomes slows aging or extends healthspan or lifespan in people. These infusions are usually sold from clinics outside FDA jurisdiction, at high prices with little oversight. For a healthy person, that is an expensive intervention with no demonstrated benefit and meaningful risk.

Yes, and it is important not to overcorrect into dismissing all of it. Bone-marrow and cord-blood transplantation, which rebuilds the blood and immune system, is decades-old, standard, life-saving care for leukemias and other blood and immune disorders, with FDA-licensed products. That is approved, established stem-cell medicine. The problem is not the concept of stem cells; it is that the specific treatments sold for joints and longevity have not earned the same approval or proof.

Deep-Dive Questions

Because the mechanism was misunderstood, rather than absent. The early hope was that injected stem cells would engraft, multiply, and turn into new cartilage, muscle, or organ tissue, essentially growing spare parts. That turned out not to happen; the cells are short-lived and are cleared quickly, and IV-given cells largely get trapped in the lungs. What the cells do while briefly alive is release a mix of signaling molecules and tiny vesicles that can dampen inflammation and nudge the surrounding tissue, a "hit and run" effect. That can plausibly reduce pain in an inflamed joint for a while. But it is a temporary chemical effect rather than the permanent regrowth the older story promised, which is why any benefit tends to be modest and short-lived rather than curative, and why "regenerative" is a generous label for most of what is on offer.

Because injecting a painful joint is one of the most placebo-prone things in medicine. The ritual of an expensive, high-tech procedure, the expectation that it will work, the attention and care around it, and the natural ups and downs of arthritis all combine to make people feel better regardless of what is in the syringe. Rigorous trials try to control for this with a placebo injection, and when they do, a large share of the apparent benefit of stem-cell injections disappears into the placebo arm. This does not mean patients are imagining their relief; placebo effects are physiologically powerful for pain. It means that the specific biological product may be adding little on top of the powerful effect of the procedure itself, which is a decisive distinction when the product costs thousands of dollars and the placebo does not.

A few features separate them plainly. A legitimate trial is registered, has oversight from an ethics board and usually the FDA, follows a written protocol, systematically tracks and reports harms, and typically costs you little or nothing, because you are contributing to answering a question that is not yet settled. A commercial clinic, by contrast, charges a large fee, often five figures, presents the treatment as established rather than experimental, may operate outside the country to avoid regulation, and rarely publishes its outcomes. If someone is selling you certainty and an invoice, be skeptical; if someone is offering you enrollment, oversight, and honesty about the unknowns, that is the trustworthy one. The paradox worth remembering is that the trustworthy version usually costs less, because proven treatments do not need to be sold this way.

The unglamorous answers are the ones with evidence behind them. For an arthritic joint, strength training around the joint, weight management, physical therapy, and, where appropriate, established injections and eventually joint replacement have far better evidence than stem-cell products, at a fraction of the cost and risk. For healthspan broadly, the levers proven to extend healthy years are the familiar ones: regular exercise including resistance training, good sleep, metabolic and cardiovascular health, not smoking, and social and cognitive engagement. They lack the novelty and the ceremony of an infusion, but they are safe, affordable, and supported by decades of evidence, which is more than any longevity drip can claim. If a regenerative treatment eventually earns firm proof, it will join that list; until then, the boring fundamentals are the better bet.

Ready when you are